NasdaqCM:VIVE

Stock Analysis Report

Executive Summary

Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions.

Snowflake

Fundamentals

Concerning outlook with weak fundamentals.


Similar Companies

Share Price & News

How has Viveve Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

48.6%

VIVE

2.0%

US Medical Equipment

1.8%

US Market


1 Year Return

-98.6%

VIVE

13.3%

US Medical Equipment

7.3%

US Market

Return vs Industry: VIVE underperformed the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: VIVE underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

VIVEIndustryMarket
7 Day48.6%2.0%1.8%
30 Day-38.5%-1.8%-0.7%
90 Day-88.7%-0.5%0.06%
1 Year-98.6%-98.6%14.2%13.3%9.7%7.3%
3 Year-99.3%-99.3%70.5%65.3%46.3%36.9%
5 Yearn/a127.0%101.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Viveve Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Viveve Medical undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Viveve Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Viveve Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Viveve Medical forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

16.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VIVE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VIVE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VIVE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VIVE's revenue (15% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: VIVE's revenue (15% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if VIVE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Viveve Medical performed over the past 5 years?

-41.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VIVE is unprofitable, and losses have increased over the past 5 years at a rate of -41.2% per year.

Accelerating Growth: Unable to compare VIVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIVE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: VIVE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: VIVE is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VIVE is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Viveve Medical's financial position?


Financial Position Analysis

Short Term Liabilities: VIVE has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VIVE has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VIVE has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: VIVE's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: VIVE has a high level of physical assets or inventory.

Debt Coverage by Assets: VIVE has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VIVE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VIVE has less than a year of cash runway if free cash flow continues to reduce at historical rates of -32.7% each year


Next Steps

Dividend

What is Viveve Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VIVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VIVE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VIVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIVE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VIVE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Viveve Medical's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Scott Durbin (50yo)

1.4yrs

Tenure

US$1,155,099

Compensation

Mr. Scott C. Durbin has been Chief Executive Officer and Director at Viveve Medical, Inc. since May 10, 2018 and also served as its Secretary since September 23, 2014. Previosuly he was Viveve Medical, Inc ...


CEO Compensation Analysis

Compensation vs. Market: Scott has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.8yrs

Average Tenure

61yo

Average Age

Experienced Management: VIVE's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

2.8yrs

Average Tenure

59yo

Average Age

Experienced Board: VIVE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$444,45902 Oct 19
Goldman Sachs Group, Investment Banking and Securities Investments
EntityCompany
Shares92,425
Max PriceUS$5.56
BuyUS$370,10230 Sep 19
Goldman Sachs Group, Investment Banking and Securities Investments
EntityCompany
Shares64,200
Max PriceUS$5.84
SellUS$136,94130 Sep 19
Goldman Sachs Group, Investment Banking and Securities Investments
EntityCompany
Shares24,817
Max PriceUS$7.53
SellUS$657,70223 Jul 19
Stonepine Capital Management LLC
EntityCompany
Shares34,034.02
Max PriceUS$42.62

Ownership Breakdown


Management Team

  • Suzon Lommel (61yo)

    Senior Vice President of Regulatory & Quality Affairs

    • Tenure: 1.8yrs
  • Deb Jorn (61yo)

    Senior Advisor to the CEO & Director

    • Tenure: 3.4yrs
    • Compensation: US$518.89k
  • Jim Robbins (55yo)

    Vice President of Finance & Administration

    • Tenure: 0yrs
    • Compensation: US$547.66k
  • Jim Atkinson (61yo)

    Chief Business Officer & President

    • Tenure: 4.7yrs
    • Compensation: US$818.12k
  • Scott Durbin (50yo)

    CEO & Director

    • Tenure: 1.4yrs
    • Compensation: US$1.16m
  • Lori McMillan

    Vice President of Human Resources

    • Tenure: 2.4yrs
  • Marty Kerber

    Vice President of Operations

    • Tenure: 1.8yrs
  • Jim Maffezzoli

    Senior Vice President of Global Marketing

    • Tenure: 1.6yrs
  • Jeannie Swindle

    Senior Director of Corporate Communications

    • Tenure: 0yrs

Board Members

  • Arlene Morris (67yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$109.81k
  • Steve Basta (53yo)

    Independent Chairman

    • Tenure: 0.8yrs
    • Compensation: US$158.60k
  • W. Stevens (65yo)

    Medical Advisor

    • Tenure: 2.8yrs
  • Deb Jorn (61yo)

    Senior Advisor to the CEO & Director

    • Tenure: 3.4yrs
    • Compensation: US$518.89k
  • Karen Zaderej (57yo)

    Independent Director

    • Tenure: 1.1yrs
    • Compensation: US$156.01k
  • Michael Krychman

    Medical Advisor

    • Tenure: 8.3yrs
  • Scott Durbin (50yo)

    CEO & Director

    • Tenure: 1.4yrs
    • Compensation: US$1.16m

Company Information

Viveve Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Viveve Medical, Inc.
  • Ticker: VIVE
  • Exchange: NasdaqCM
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$7.700m
  • Shares outstanding: 1.60m
  • Website: https://www.viveve.com

Number of Employees


Location

  • Viveve Medical, Inc.
  • Building B
  • Suite 250
  • Englewood
  • Colorado
  • 80112
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VIVENasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDApr 2016

Biography

Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency gener ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:18
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.